Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra) on weekly and biweekly schedules
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CSL Behring
- 30 Jan 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.